Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PREDIX Luminal A neoadjuvant endocrine therapy ± palbociclib in hormone receptor–positive breast cancer
2014-000809-12Phase 2Terminated
- Sponsor
- Karolinska University Hospital
- Start
- Sep 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised trial of palbociclib in breast cancer (2 arms), sponsored by Karolinska University Hospital. Primary endpoint: Pathological objective response to primary medical treatment. Started Sep 2014; status: terminated.
02
Drugs
palbociclib
03
Conditions
breast cancer
Beyond the preview
Go deeper on 2014-000809-12.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-000809-12.